BCAX insider buying and SEC filings, explained
Bicara Therapeutics Inc. · CIK 2023658
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$4.8M
Insiders who bought
1
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$9.9M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 8, 2026 | Planned (10b5-1) | Ryan Cohlhepp (CEO and Director) sold 17,500 shares at about $22.90 ($401K), marked as a 10b5-1 plan trade. Holdings down 9% to 181,641 shares. | SEC filing Filed Sep 10, 2026 |
| Aug 10, 2026 | Planned (10b5-1) | Ivan Hyep (CFO) sold 12,500 shares at about $27.97 ($350K), marked as a 10b5-1 plan trade. Holdings down 9% to 129,855 shares. | SEC filing Filed Aug 12, 2026 |
| Aug 10, 2026 | Planned (10b5-1) | Claire Mazumdar (CEO and Director) sold 10,000 shares at about $27.98 ($280K), marked as a 10b5-1 plan trade. Holdings down 3% to 362,152 shares. | SEC filing Filed Aug 12, 2026 |
| Aug 10, 2026 | Planned (10b5-1) | Ryan Cohlhepp (President / COO and Director) sold 18,750 shares at about $27.98 ($525K), marked as a 10b5-1 plan trade. Holdings down 9% to 181,641 shares. | SEC filing Filed Aug 12, 2026 |
| Jul 10, 2026 | Planned (10b5-1) | Claire Mazumdar (CEO and Director) sold 10,000 shares at about $28.42 ($284K), marked as a 10b5-1 plan trade. Holdings down 3% to 362,152 shares. | SEC filing Filed Jul 14, 2026 |
| Jul 8–9, 2026 | Planned (10b5-1) | Ryan Cohlhepp (President / COO and Director) sold 28,750 shares between Jul 8 and Jul 9 at about $28.98 ($833K), marked as a 10b5-1 plan trade. Holdings down 14% to 181,641 shares. | SEC filing Filed Jul 10, 2026 |
| Jul 8, 2026 | Planned (10b5-1) | Ivan Hyep (CFO) sold 28,000 shares at about $28.84 ($808K), marked as a 10b5-1 plan trade. Holdings down 18% to 129,855 shares. | SEC filing Filed Jul 10, 2026 |
| May 21, 2026 | Planned (10b5-1) | Ivan Hyep (CFO) sold 9,200 shares at about $20.42 ($188K), marked as a 10b5-1 plan trade. Holdings down 6% to 145,355 shares. | SEC filing Filed May 26, 2026 |
| May 18, 2026 | Planned (10b5-1) | Claire Mazumdar (CEO and Director) sold 15,000 shares at about $20.04 ($301K), marked as a 10b5-1 plan trade. Holdings down 4% to 362,152 shares. | SEC filing Filed May 20, 2026 |
| May 15, 2026 | Planned (10b5-1) | Ryan Cohlhepp (President / COO and Director) sold 12,500 shares at about $20.29 ($254K), marked as a 10b5-1 plan trade. Holdings down 6% to 191,641 shares. | SEC filing Filed May 18, 2026 |
| Apr 27, 2026 | Planned (10b5-1) | David Raben (Chief Medical Officer) sold 5,500 shares at about $22.88 ($126K), marked as a 10b5-1 plan trade. Holdings down 9% to 55,286 shares. | SEC filing Filed Apr 28, 2026 |
| Apr 21, 2026 | Planned (10b5-1) | Ivan Hyep (CFO) sold 9,200 shares at about $23.00 ($212K), marked as a 10b5-1 plan trade. Holdings down 6% to 145,355 shares. | SEC filing Filed Apr 22, 2026 |
| Apr 20, 2026 | Planned (10b5-1) | Claire Mazumdar (CEO and Director) sold 15,000 shares at about $23.61 ($354K), marked as a 10b5-1 plan trade. Holdings down 4% to 362,152 shares. | SEC filing Filed Apr 20, 2026 |
| Apr 15, 2026 | Planned (10b5-1) | Ryan Cohlhepp (President / COO and Director) sold 12,500 shares at about $23.01 ($288K), marked as a 10b5-1 plan trade. Holdings down 6% to 196,141 shares. | SEC filing Filed Apr 17, 2026 |
| Mar 25, 2026 | Planned (10b5-1) | David Raben (Chief Medical Officer) sold 5,500 shares at about $18.95 ($104K), marked as a 10b5-1 plan trade. Holdings down 9% to 55,286 shares. | SEC filing Filed Mar 26, 2026 |
| Mar 23, 2026 | Planned (10b5-1) | Ivan Hyep (CFO) sold 9,200 shares at about $18.52 ($170K), marked as a 10b5-1 plan trade. Holdings down 6% to 145,355 shares. | SEC filing Filed Mar 24, 2026 |
| Mar 18–20, 2026 | Planned (10b5-1) | Claire Mazumdar (CEO and Director) sold 15,000 shares between Mar 18 and Mar 20 at about $18.82 ($282K), marked as a 10b5-1 plan trade. Holdings down 4% to 339,392 shares. | SEC filing Filed Mar 20, 2026 |
| Mar 16, 2026 | Planned (10b5-1) | Ryan Cohlhepp (President / COO and Director) sold 12,500 shares at about $19.66 ($246K), marked as a 10b5-1 plan trade. Holdings down 6% to 200,641 shares. | SEC filing Filed Mar 17, 2026 |
| Mar 9, 2026 | Planned (10b5-1) | Claire Mazumdar (CEO and Director) sold 36,766 shares at about $19.17 ($705K), marked as a 10b5-1 plan trade. Holdings down 10% to 339,392 shares. | SEC filing Filed Mar 11, 2026 |
| Mar 4–6, 2026 | Planned (10b5-1) | Claire Mazumdar (CEO and Director) sold 8,234 shares between Mar 4 and Mar 6 at about $18.74 ($154K), marked as a 10b5-1 plan trade. Holdings down 2% to 339,392 shares. | SEC filing Filed Mar 6, 2026 |
| Mar 3, 2026 | Planned (10b5-1) | Ryan Cohlhepp (President / COO and Director) sold 17,392 shares at about $18.16 ($316K), marked as a 10b5-1 plan trade. Holdings down 8% to 205,141 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 3–4, 2026 | Planned (10b5-1) | Ivan Hyep (CFO) sold 16,518 shares between Mar 3 and Mar 4 at about $18.23 ($301K), marked as a 10b5-1 plan trade. Holdings down 10% to 145,355 shares. | SEC filing Filed Mar 5, 2026 |
| Mar 3–4, 2026 | Planned (10b5-1) | David Raben (Chief Medical Officer) sold 16,500 shares between Mar 3 and Mar 4 at about $18.52 ($306K), marked as a 10b5-1 plan trade. Holdings down 23% to 55,286 shares. | SEC filing Filed Mar 5, 2026 |
| Feb 26, 2026 | Other purchase | Peter Kolchinsky (Director and 10% owner) bought 2,200,000 Pre-Funded Warrant (Right to Buy) indirectly at $16.00 ($35.2M), reported as a purchase (code P). New position of 2,200,000 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 4 other reporting owners. | SEC filing Filed Mar 2, 2026 |
| Feb 26, 2026 | Purchase (code P) | Peter Kolchinsky (Director and 10% owner) bought 300,000 shares indirectly at $16.00 ($4.8M), reported as a purchase (code P). Indirect holdings up 7% to 4,603,418 shares. Not marked as a 10b5-1 plan trade. Filed jointly with 4 other reporting owners. | SEC filing Filed Mar 2, 2026 |
| Feb 25, 2026 | Planned (10b5-1) | Ryan Cohlhepp (President / COO and Director) sold 3,631 shares at about $18.04 ($66K), marked as a 10b5-1 plan trade. Holdings down 2% to 209,641 shares. | SEC filing Filed Feb 27, 2026 |
| Jan 22, 2026 | Planned (10b5-1) | Ryan Cohlhepp (President / COO and Director) sold 3,828 shares at about $18.10 ($69K), marked as a 10b5-1 plan trade. Holdings down 2% to 210,164 shares. | SEC filing Filed Jan 26, 2026 |
| Jan 22, 2026 | Planned (10b5-1) | Ivan Hyep (CFO) sold 1,882 shares at about $18.15 ($34K), marked as a 10b5-1 plan trade. Holdings down 1% to 145,355 shares. | SEC filing Filed Jan 26, 2026 |
| Jan 15, 2026 | Planned (10b5-1) | Ryan Cohlhepp (President / COO and Director) sold 149 shares at $18.02 ($3K), marked as a 10b5-1 plan trade. Holdings down <1% to 213,992 shares. | SEC filing Filed Jan 20, 2026 |
| Dec 22, 2025 | Planned (10b5-1) | Ivan Hyep (CFO) sold 9,200 shares at about $18.31 ($168K), marked as a 10b5-1 plan trade. Holdings down 6% to 145,355 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 15, 2025 | Planned (10b5-1) | Ryan Cohlhepp (President / COO and Director) sold 12,500 shares at about $18.68 ($234K), marked as a 10b5-1 plan trade. Holdings down 6% to 189,141 shares. | SEC filing Filed Dec 16, 2025 |
| Nov 24–25, 2025 | Planned (10b5-1) | David Raben (Chief Medical Officer) sold 11,000 shares between Nov 24, 2025 and Nov 25, 2025 at about $18.65 ($205K), marked as a 10b5-1 plan trade. Holdings down 24% to 35,497 shares. | SEC filing Filed Nov 25, 2025 |
| Nov 24, 2025 | Planned (10b5-1) | Claire Mazumdar (CEO and Director) sold 41,163 shares at about $18.86 ($776K), marked as a 10b5-1 plan trade. Holdings down 12% to 309,892 shares. | SEC filing Filed Nov 25, 2025 |
| Nov 21–24, 2025 | Planned (10b5-1) | Ivan Hyep (CFO) sold 18,400 shares between Nov 21, 2025 and Nov 24, 2025 at about $18.54 ($341K), marked as a 10b5-1 plan trade. Holdings down 11% to 145,355 shares. | SEC filing Filed Nov 25, 2025 |
| Nov 21, 2025 | Planned (10b5-1) | Ryan Cohlhepp (President / COO and Director) sold 12,500 shares at about $18.05 ($226K), marked as a 10b5-1 plan trade. Holdings down 6% to 193,641 shares. | SEC filing Filed Nov 25, 2025 |
50 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow BCAX in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.